Zak Mir talks to Anthony Tennyson, CEO Solvonis, in the wake of the clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, announcing positive results from pre-clinical screening in its SVN-SDN-14 programme, identifying three high-performing candidates to advance into in vivo studies for people living with Post-Traumatic Stress Disorder (PTSD).
